FTO and neoplasm: FTO [47], RBMX [48], METTL3 [5], and METTL14 [49, 50], have been demonstrated to be tumor proto-oncogenes or biomarkers through m6A, with METTL3 serving as a pathological diagnostic index and potential therapeutic target for ESCA [5], and with RBMX encoding HNRNPG to affect m6A, also a member of the hnRNPs family [51].